Filip Dubovsky - May 14, 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role: President, R&D
Signature: /s/ Mark J. Casey, Attorney-in-Fact
Stock symbol: NVAX
Transactions as of: May 14, 2024
Transactions value $: -$520,662
Form type: 4
Date filed: 5/15/2024, 09:15 PM
Previous filing: Mar 12, 2024
Next filing: Jun 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVAX	Common Stock	Options Exercise	$137K	+19.7K	+29.5%	$6.97	86.3K	May 14, 2024	Direct
transaction	NVAX	Common Stock	Sale	-$658K	-47.3K	-54.84%	$13.90	39K	May 14, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVAX	Stock Option (Right to Buy)	Options Exercise	$0	-19.7K	-29.17%	$0.00	47.7K	May 14, 2024	Common Stock	19.7K	$6.97	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $14.00, inclusive. The Reporting Person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2	Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the March 7, 2023 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.

Content

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $14.00, inclusive. The Reporting Person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the March 7, 2023 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.